Efficacy and Safety of Leriglitazone in Adult Male subjects with cALD

• Research type

  Research Study

• Full title

  A Clinical study to assess the efficacy and safety of Leriglitazone in Adult Male subject with Cerebral Adrenoleukodystrophy

• IRAS ID

  1010666

• Contact name

  Arun Mistry

• Contact email

  info@minoryx.com

• Sponsor organisation

  Minoryx Therapeutics S.L.

• Eudract number

  2024-515104-39

• Clinicaltrials.gov Identifier

  NCT05819866

• Research summary

  This study will test a drug called leriglitazone that may slow the damage to brain cells. This study will investigate how effective and safe leriglitazone is for treating cALD in adults by comparing it with placebo (a substance that contains no active medicine).

• REC name

  London - Brent Research Ethics Committee

• REC reference

  24/LO/0683

• Date of REC Opinion

  11 Nov 2024

• REC opinion

  Further Information Favourable Opinion